Refludan and Chest pain - a phase IV clinical study of FDA data

Summary:

Chest pain is reported as a side effect among people who take Refludan (lepirudin recombinant), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Heparin, and have Heparin-induced thrombocytopenia.

The phase IV clinical study analyzes which people have Chest pain when taking Refludan. It is created by eHealthMe based on reports of 539 people who have side effects when taking Refludan from the FDA, and is updated regularly.

What is Refludan?

Refludan has active ingredients of lepirudin recombinant. eHealthMe is studying from 540 Refludan users. Check the latest studies of Refludan.

What is Chest pain?

Chest pain is found to be associated with 3,467 drugs and 4,888 conditions by eHealthMe. Check the latest studies of Chest pain.

On Jul, 16, 2026

539 people reported to have side effects when taking Refludan.
Among them, 14 people (2.6%) have Chest pain.

Among these 14 people:

How long have people been on Refludan when they have Chest pain? *

What is the gender of people who have Chest pain when taking Refludan? *

female: 78.57 %
male: 21.43 %

What is the age of people who have Chest pain when taking Refludan? *

What are other drugs people take besides Refludan? *

What are other side effects people have besides Chest pain? *

Dyspnea (difficult or laboured breathing): 7 people, 50.00%
Hypotension (abnormally low blood pressure): 6 people, 42.86%
Anaphylaxis (serious allergic reaction that is rapid in onset and may cause death): 5 people, 35.71%
Activated Partial Thromboplastin Time Prolonged: 5 people, 35.71%
Nausea (feeling of having an urge to vomit): 4 people, 28.57%
Leukocytosis (increased white blood cells): 3 people, 21.43%
Fever: 3 people, 21.43%
Atelectasis (partial or complete collapse of the lung): 3 people, 21.43%
Stress And Anxiety: 3 people, 21.43%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 3 people, 21.43%

What are the existing conditions these people have? *

Heparin-Induced Thrombocytopenia: 4 people, 28.57%
Thrombocytopenia (decrease of platelets in blood): 2 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Refludan and have Chest pain?

- Check whether Chest pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Refludan:

Refludan (540 reports)

Chest pain treatments and more:

Chest pain (363,501 reports)

Browse all side effects of Refludan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Chest pain:

Chest pain (3,467 drugs)

Browse all the conditions that are associated with Chest pain:

Chest pain (4,888 conditions)

Related publications that referenced our studies

Pang, T., & Gudi, A., "Chest pain following the use of fluvoxamine in depression", Proceedings of Singapore Healthcare, 2018 Jan .
Pang, T., & Gudi, A., "Chest pain following the use of fluvoxamine in depression", Proceedings of Singapore Healthcare, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on lepirudin recombinant (the active ingredients of Refludan) and Refludan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.